VFA
CHRS icon

Virtus Fund Advisers’s Coherus Oncology CHRS Stock Holding History

Virtus Fund Advisers’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13,663
Closed -$289K – 527
2017
Q1 		$289K Sell
13,663
-882
-6% -$21.7K ﹤0.01% 387
2016
Q4 		$409K Hold
14,545
– – ﹤0.01% 359
2016
Q3 		$390K Buy
+14,545
New +$397K ﹤0.01% 366

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Virtus Fund Advisers's CHRS Position: Q2 2017 in Review

Virtus Fund Advisers sold out of Coherus Oncology (CHRS) in Q2 2017, closing a stake of 13,663 shares — an estimated $289K sold.

Virtus Fund Advisers first reported a position in CHRS in Q3 2016 and held it in 3 quarters. The position peaked at $409K in Q4 2016. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

  • Virtus Fund Advisers reported no remaining Coherus Oncology position as of Q2 2017 after selling out during the quarter.
  • Virtus Fund Advisers sold 13,663 Coherus Oncology shares in Q2 2017, an estimated $289K.
  • Virtus Fund Advisers first reported a position in Coherus Oncology in Q3 2016 and held it in 3 quarters.
  • Virtus Fund Advisers's Coherus Oncology position peaked at $409K in Q4 2016.
  • 106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on Virtus Fund Advisers's 13F filing for Q2 2017, filed 11 Aug 2017.